Trastuzumab plus chemotherapy: convincing survival benefit or not?
- PMID: 15911863
- DOI: 10.1200/JCO.2005.12.903
Trastuzumab plus chemotherapy: convincing survival benefit or not?
Comment on
-
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.J Clin Oncol. 2005 Jul 1;23(19):4265-74. doi: 10.1200/JCO.2005.04.173. Epub 2005 May 23. J Clin Oncol. 2005. PMID: 15911866 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical